PatentJun 18, 2026, 07:31 AM
PMGC Holdings Files New Patents for Muscle Preservation in GLP-1 Weight Loss
AI Summary
PMGC Holdings Inc., through its wholly-owned subsidiary NorthStrive Biosciences, Inc., announced the filing of two new U.S. patent applications for its EL-22 and EL-32 compounds. These applications expand the company's intellectual property portfolio into potential human pharmaceutical applications, specifically targeting the preservation of lean muscle mass during GLP-1 and obesity-related weight loss. This strategic move aims to address an emerging need in the rapidly growing GLP-1 market, differentiating NorthStrive's portfolio from its previous animal-focused filings.
Key Highlights
- NorthStrive Biosciences filed two new U.S. patent applications for EL-22 and EL-32.
- Applications expand intellectual property into human pharmaceutical use for preserving lean muscle mass.
- Targets muscle loss during GLP-1 and obesity-related weight loss treatments.
- Covers sarcopenia, malnutrition, neurogenic atrophy, and physical inactivity.
- Includes combination approaches with apelin or ursolic acid for muscle support.
- EL-22 claims involve Myo-2 peptide constructs; EL-32 claims involve microorganisms.
- Applications cover various delivery forms including oral, injectable, nasal, and topical.
Price Impact
More from ELAB